Member Info for Ivyspivey

Not in here guys and surevyou are aware NM is at event in London on 26th but just in case Panel III – Anti Bacterial/microbiome Moderator: Sarah Haywood, CEO, MedCity Panel: • Richard Mason, Head of J&J Innovation, London, J&J • Graham Lumsden, CEO, Motif Bio • Neil Murray, CEO, Redx • Glyn Edwards, CEO, Summit GLA

Not in here guys-mistake on my part but sure you are aware of GE being at event in London on 26th Jan but just in case Panel III – Anti Bacterial/microbiome Moderator: Sarah Haywood, CEO, MedCity Panel: • Richard Mason, Head of J&J Innovation, London, J&J • Graham Lumsden, CEO, Motif Bio • Neil Murray, CEO, Redx • Glyn Edwards, CEO, Summit

The idea of super lice is mainly due to resistance issues to synthetic pyrethroids like permethrin etc.All these types of product will quickly acquire cross resistance hence a big problem but think that TYRU technology is totally untelated hence should be very effective.

Nice update

Can anyone give an unbiased account of the investment performance of ONZrecently re SP movements of FCR/JLP and the others as these are not companys I follow-also the value of the large number of warrants/options they currently hold. Think most of us think N4 investment is a good one. Just trying to get a better view on why some people are so unhappy with GB-is it just lack of comms,has the investment performance been so bad apart from obviously contravening it's stated investment policy leading to suspension. I know he has a chequered history with Globo etc but just trying to get handle on him.Think NT comment about like the way he operates maybe more to do with he lets him get on with N4 rather than interfering as opposed to him liking his "barrow boy" style.

Yes mate lot of difference between bad decisions like breaching investment policy of some sort of pre meditated fraud,which I agree is not the case here. In this type of situation I also think control the controllable and don't worry about the uncontrollable.Letting off steam is fine but let us keep it in perspective and if necessary talk off a public forum. First establish the "facts" not rumours or frustrations due to lack of comms. Then react accordingly -so we are in suspension so we can't trade so no point in reflecting on potential losses etc as we simply don't know what will happen. By all means make comments about lack of comms etc and inactivity but bear in mind it could effect senti ent which does no good to any genuine holders here. By all means continue to contact GB or NT and report back but better to be polite and not hostile imo. No problems about talking about taking some action but make sure you know exactly what it's purpose is and what the action us about and what chance does it have in succeeding. Only my thoughts as usual and happy for folk to take contrarian view

Just listened and though OK summary So few companies are total frauds. Burnell creation Globo (GBO) was but Onzima (ONZ) is not. So what happens if you lose money on this company or another which goes horribly wrong? - See more at: http://www.*************.com/views/26410/tom-winnifrith-bearcast-back-to-gavin-burnell-at-globo-onzima-not-every-aim-disaster-is-fraud-most-are-not#sthash.uNJtOdCf.dpuf

CPN announcement and admission of shares

l be published at some point in the final six months of 2017. Amryt Pharma Here’s another junior druggie that has been very busy but doesn’t seem to have garnered the market plaudits it deserves. In 18 months it has it has managed two acquisitions, two stock market listings and raised €43mln. Oh, and it has put a heavy-hitting team together that supports a very ambitious growth strategy. Earlier this month it landed a €20mln European Investment Bank debt facility that will help fund a late stage clinical study of a potentially breakthrough treatment called Episalvan for a rare skin disease. The cash will pay for a phase III trial to demonstrate efficacy and safety, which is expected to get underway in the first-quarter of 2017. Early data from patients with Epidermolysis Bullosa (EB) will be available by mid-2018 with full commercial launch of the product expected the year after. EB is an inherited disorder where the skin becomes very fragile. The market for the new treatment is thought to be worth US$1.5bn a year. The funding package is important as it spares investors dilution that would have come if Amryt Pharmaceuticals (LON:AMYT) had issued shares to bankroll the development of Episalvan. The product is approved for use in adults in a type of gash or ulcer called a partial thickness wound. It is a case now of proving the treatment works for EB. It does have competition in the EB market in the form of a drug coming to the market developed by NASDAQ-listed Amicus Therapeutics. Some experts say Amicus’s product has a slightly inferior profile to Episalvan, yet it is valued by analysts at €326mln (US$350mln). Amyrt’s market capitalisation currently stands at €48mln, so there’s a valuation disconnect there. The anomaly hasn’t escaped chief executive Joe Wiley and the team, who, longer term, may look to list the business on NASDAQ (while keeping its stock market quote here). Amryt expects phase III trials of Episalvan to begin early next year and is already making plans for a commercial launch the year after.

Paragon Entertainment Limited (AIM:PEL), the attractions design, production and fit-out business, announces that on 28 November 2016, Scott Dickinson, Finance Manager and a PDMR of the Company, purchased 324,456 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") at an average price of 3.58 pence per Ordinary Share (the "Purchase"). Following the Purchase, Scott Dickinson and persons closely associated with him are beneficially interested in 324,456 Ordinary Shares, representing 0.2% of the Company's issued share capital.

Hi Jesk Equally disappointed with SP action here but think good potential,with Vammouse and Purescience. With horses yes flys can be an issue but mosquitos and ticks are not really the target in equine but in both domestic and particularly in production animals where the senior Managements expertise lies.

Sorry should have clarified-major market shift not really Vamoose but parasite control from conventional killing via GABA receptors etc to a more natural appriach

Hi S&S Hope you are well.Agree re Ex. Merial connections that there would be lots of contacts but Merial and BI are currently in process of " integration" so until finalised no decisions re TYRU. Also if you look at Current Merial Ecto P/F re Nexgard then it would take a major market shift for them to want to go for Vamoose. Not saying once established the TYRU AH Purscience range will not be a takeover targe but may not be from conventional AH outfits

The Lush Training Prize aims to recognise and reward those working to eliminate animal testing in science and cosmetics through training. Kirkstall is a UK-based biotechnology company dedicated to changing researchers’ perspectives on animal replacement and in vitro testing, and it is for their work doing so that they have won one of this year’s two training prizes. Can we confirm if Kirkstall won this prize-lots of newsflow on Kirkstall site

Yes Jimzi Bought a few at 2.75,and next buy quotecwas 3.25 so tells a story as you said.

See NT is still tweeting-only a retweet of Gates Foundation endorsing use of Vaccines in general but he is certainly not hiding so happy to wait. News will cone when ready-no No point in sweating ahead of it-only worry about the controllable.

Absolutely This is suspended so no point in speculating about any spectacular outcome positive or negative. Strongly suggest no poster knows any more than anyone else so anyone keen to publish a opinion like it is going bust is utter BS-it was suspended due to failing to RTO in time not due at any financial irregularity

If a treatment passes phase 3 via FDA or EMA then even if they have different clinical end points which can be the case the correlation between a successful approval by the second body is very high. Phase 3 tests both efficacy and safety on a much bigger scale than p1/p2. All drugs or medicines have clinical effects in addition to their beneficial ones and have to be recorded on the SPC. Your comment about benefits outweighing its risks and therefore gaining approval is lukewarm to say the least and demonstrates a total failure to understand the degree that these benefits outweigh the risks to secure the necessary approval. This is not a non iniferiority trial as I understand it so as EB says it showed a significant difference in efficacy to the conparator

Good to keep discussion going even if there is nothing any of us can do ATM.Do find it strange for anyone to be overtly negative as can't make any difference but just trying to pray on people's fears which we know can run rife on AIM and in suspended companys the most. My take is it is just due to AIM rules and the only people who know what is going on is the BOD and as NT has so much money in here his interests are fully aligned with ours so happy enough to wait for news

With all these bio pharma shares it is essentially about risk/reward.To have a phase 3 ready asset in a nice space is a real positive and then add in the great BOD(both scientific and commercial) then you see what the upside is here